Literature DB >> 28401189

p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding.

Oleg Timofeev1, Thorsten Stiewe1.   

Abstract

Mutations in cancer abolish normal tumor suppressive functions of tumor protein p53 (TP53, best known as p53) and convert it into an oncogene. We recently reported the identification of ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) as a transcriptional target of mutant p53 that enhances folding of N-glycosylated proteins required for cancer cell migration, invasion, and metastasis.

Entities:  

Keywords:  ENTPD5; N-glycosylation; metastasis; mutant p53; protein folding

Year:  2017        PMID: 28401189      PMCID: PMC5383355          DOI: 10.1080/23723556.2017.1288678

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN: 2372-3556


  10 in total

Review 1.  Glycosylation-directed quality control of protein folding.

Authors:  Chengchao Xu; Davis T W Ng
Journal:  Nat Rev Mol Cell Biol       Date:  2015-10-14       Impact factor: 94.444

Review 2.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

Review 3.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

4.  A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.

Authors:  Maddalena Adorno; Michelangelo Cordenonsi; Marco Montagner; Sirio Dupont; Christine Wong; Byron Hann; Aldo Solari; Sara Bobisse; Maria Beatrice Rondina; Vincenza Guzzardo; Anna R Parenti; Antonio Rosato; Silvio Bicciato; Allan Balmain; Stefano Piccolo
Journal:  Cell       Date:  2009-04-03       Impact factor: 41.582

5.  Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.

Authors:  Susann Weissmueller; Eusebio Manchado; Michael Saborowski; John P Morris; Elvin Wagenblast; Carrie A Davis; Sung-Hwan Moon; Neil T Pfister; Darjus F Tschaharganeh; Thomas Kitzing; Daniela Aust; Elke K Markert; Jianmin Wu; Sean M Grimmond; Christian Pilarsky; Carol Prives; Andrew V Biankin; Scott W Lowe
Journal:  Cell       Date:  2014-04-10       Impact factor: 41.582

6.  Mutant p53 drives invasion by promoting integrin recycling.

Authors:  Patricia A J Muller; Patrick T Caswell; Brendan Doyle; Marcin P Iwanicki; Ee H Tan; Saadia Karim; Natalia Lukashchuk; David A Gillespie; Robert L Ludwig; Pauline Gosselin; Anne Cromer; Joan S Brugge; Owen J Sansom; Jim C Norman; Karen H Vousden
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

7.  Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients.

Authors:  Yasmine Zerdoumi; Juliette Aury-Landas; Catherine Bonaïti-Pellié; Céline Derambure; Richard Sesboüé; Mariette Renaux-Petel; Thierry Frebourg; Gaëlle Bougeard; Jean-Michel Flaman
Journal:  Hum Mutat       Date:  2013-02-11       Impact factor: 4.878

8.  Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.

Authors:  Fotini Vogiatzi; Dominique T Brandt; Jean Schneikert; Jeannette Fuchs; Katharina Grikscheit; Michael Wanzel; Evangelos Pavlakis; Joël P Charles; Oleg Timofeev; Andrea Nist; Marco Mernberger; Eva J Kantelhardt; Udo Siebolts; Frank Bartel; Ralf Jacob; Ariane Rath; Roland Moll; Robert Grosse; Thorsten Stiewe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 11.205

9.  Cytoplasmic gain-of-function mutant p53 contributes to inflammation-associated cancer.

Authors:  Arianna Bellazzo; Giulio Di Minin; Licio Collavin
Journal:  Mol Cell Oncol       Date:  2015-01-23

Review 10.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

  10 in total
  3 in total

1.  Knockdown of ENTPD5 inhibits tumor metastasis and growth via regulating the GRP78/p-eIF-2α/CHOP pathway in serous ovarian cancer.

Authors:  Xueping Chen; Zhiqiang Zha; Yu Wang; Yun Chen; Menglan Pang; Liping Huang; Yao Chen
Journal:  J Ovarian Res       Date:  2022-06-07       Impact factor: 5.506

2.  Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.

Authors:  Anthony Dominijanni; William H Gmeiner
Journal:  Cancer Drug Resist       Date:  2018-03-19

Review 3.  p53's Extended Reach: The Mutant p53 Secretome.

Authors:  Evangelos Pavlakis; Thorsten Stiewe
Journal:  Biomolecules       Date:  2020-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.